Novel Aptamers Targeting Sclerostin Loop3 Improve Skeletal and Muscle Properties Without Adverse Cardiovascular Effects in Orchiectomized Mice
ABSTRACT Background The Wnt/β‐catenin pathway and its bone‐specific inhibitor, sclerostin, play important roles in skeletal development and homeostasis. The humanized sclerostin antibody, romosozumab, can significantly increase bone mineral density (BMD) of patients with osteoporosis, but it may als...
Saved in:
| Main Authors: | Bingna Zhou, Jing Hu, Yuanyuan Yu, Lei Sun, Yanye Wang, Qian Zhang, Yan Jiang, Ou Wang, Xiaoping Xing, Weibo Xia, Luyao Wang, Ge Zhang, Mei Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.13831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus
by: Cyril Traechslin, et al.
Published: (2025-06-01) -
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
by: Shi-Hsun Chiu, et al.
Published: (2024-12-01) -
Sclerostin as a new target of diabetes-induced osteoporosis
by: Yanhua Li, et al.
Published: (2024-12-01) -
The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomography
by: Laurence Ferrières, et al.
Published: (2025-06-01) -
Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01)